Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075998 · ClinicalTrials.gov registry record · Phase 3
The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3 study, sponsored by InterMune.
- Terminated
- Registry status
- Phase 3
- Development phase
- 826
- Enrollment target
NCT00075998 is a Phase 3 study that was terminated before completion, run by InterMune. The registered enrollment target is 826 participants.
The verdict
NCT00075998, a Phase 3 study, was terminated before completion, sponsored by InterMune.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 826 participants
- Enrollment target
Study Summary
* Purpose: A phase 3, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of 200 µg of recombinant Interferon gamma-1b administered by subcutaneous (SC) injection, compared with placebo, in patients with IPF * Enrollment: Approximately 800 patients will be enrolled from approximately 80 centers in North America and Europe * Randomization: 2:1 active-to-placebo ratio * Duration: at least 2 years active drug or placebo (rescue therapy will be permitted for patients who meet predefined criteria)
Interventions
- DRUG Interferon gamma-1b ("Actimmune")
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 826 participants |
| Start Date | 2003-12 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075998
The ClinicalTrials.gov registry entry for NCT00075998 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 826 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InterMune, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon gamma-1b ("Actimmune") is the first listed.
NCT00075998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00075998 about?
NCT00075998 is a clinical study titled "The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)". * Purpose: A phase 3, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of 200 µg of recombinant Interferon gamma-1b administered by subcutaneous (SC) injection, compared with placebo, in patients with IPF * Enrollment: Approximately 800 patients will be enrolle...
What is the current status of trial NCT00075998?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 826 participants. The study started on 2003-12. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00075998?
The interventions under investigation include: Interferon gamma-1b ("Actimmune") (DRUG).
Who is sponsoring clinical trial NCT00075998?
This trial is sponsored by InterMune, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.